Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Pro Medicus Limited (PMCUF) vs. Competitors

39 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
PMCUFPro Medicus Limited$127.25$13.38B74.91-21.48%Strong BuyUnlock the PMCUF analyst price target with TipRanks PremiumPMCUFUnlock the PMCUF top-analyst price target with TipRanks Premium
AU:M7TMach7 TechnologiesAUD 0.26AUD 61.10M-6.84-21.21%Moderate BuyUnlock the AU:M7T analyst price target with TipRanks PremiumPMCUF vs AU:M7TUnlock the AU:M7T top-analyst price target with TipRanks Premium
AU:BMTBeamtree Holdings LtdAUD 0.07AUD 20.08M-1.08-66.00%Moderate BuyUnlock the AU:BMT analyst price target with TipRanks PremiumPMCUF vs AU:BMTUnlock the AU:BMT top-analyst price target with TipRanks Premium
AU:SHGSingular Health Group LtdAUD 0.19AUD 60.33M-9.11-36.21%Moderate BuyUnlock the AU:SHG analyst price target with TipRanks PremiumPMCUF vs AU:SHGUnlock the AU:SHG top-analyst price target with TipRanks Premium
AU:AYAArtrya LimitedAUD 2.59AUD 425.86M-14.60-10.69%Strong BuyUnlock the AU:AYA analyst price target with TipRanks PremiumPMCUF vs AU:AYAUnlock the AU:AYA top-analyst price target with TipRanks Premium
AU:ALCAlcidion Group LimitedAUD 1.22AUD 164.00M73.5310.45%Moderate BuyUnlock the AU:ALC analyst price target with TipRanks PremiumPMCUF vs AU:ALCUnlock the AU:ALC top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
PMCUFPro Medicus Limited127.25-33.69-20.93%
AU:M7TMach7 Technologies0.26-0.09-25.71%
AU:BMTBeamtree Holdings Ltd0.07-0.13-66.00%
AU:SHGSingular Health Group Ltd0.18-0.09-32.73%
AU:AYAArtrya Limited2.59-0.58-18.30%
AU:ALCAlcidion Group Limited1.220.2221.50%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts